191 related articles for article (PubMed ID: 31477558)
1. Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
Joharatnam-Hogan N; Cafferty F; Hubner R; Swinson D; Sothi S; Gupta K; Falk S; Patel K; Warner N; Kunene V; Rowley S; Khabra K; Underwood T; Jankowski J; Bridgewater J; Crossley A; Henson V; Berkman L; Gilbert D; Kynaston H; Ring A; Cameron D; Din F; Graham J; Iveson T; Adams R; Thomas A; Wilson R; Pramesh CS; Langley R;
Lancet Gastroenterol Hepatol; 2019 Nov; 4(11):854-862. PubMed ID: 31477558
[TBL] [Abstract][Full Text] [Related]
2. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
Coyle C; Cafferty FH; Rowley S; MacKenzie M; Berkman L; Gupta S; Pramesh CS; Gilbert D; Kynaston H; Cameron D; Wilson RH; Ring A; Langley RE;
Contemp Clin Trials; 2016 Nov; 51():56-64. PubMed ID: 27777129
[TBL] [Abstract][Full Text] [Related]
3. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. High-dose oral vitamin D supplementation and mortality in people aged 65-84 years: the VIDAL cluster feasibility RCT of open versus double-blind individual randomisation.
Rake C; Gilham C; Bukasa L; Ostler R; Newton M; Peto Wild J; Aigret B; Hill M; Gillie O; Nazareth I; Sasieni P; Martineau A; Peto J
Health Technol Assess; 2020 Feb; 24(10):1-54. PubMed ID: 32090730
[TBL] [Abstract][Full Text] [Related]
7. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial.
Hull MA; Sprange K; Hepburn T; Tan W; Shafayat A; Rees CJ; Clifford G; Logan RF; Loadman PM; Williams EA; Whitham D; Montgomery AA;
Lancet; 2018 Dec; 392(10164):2583-2594. PubMed ID: 30466866
[TBL] [Abstract][Full Text] [Related]
8. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
[TBL] [Abstract][Full Text] [Related]
9. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial.
Burn J; Sheth H; Elliott F; Reed L; Macrae F; Mecklin JP; Möslein G; McRonald FE; Bertario L; Evans DG; Gerdes AM; Ho JWC; Lindblom A; Morrison PJ; Rashbass J; Ramesar R; Seppälä T; Thomas HJW; Pylvänäinen K; Borthwick GM; Mathers JC; Bishop DT;
Lancet; 2020 Jun; 395(10240):1855-1863. PubMed ID: 32534647
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Chen LT
Lancet; 2017 Dec; 390(10111):2461-2471. PubMed ID: 28993052
[TBL] [Abstract][Full Text] [Related]
11. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
Cunningham D; Stenning SP; Smyth EC; Okines AF; Allum WH; Rowley S; Stevenson L; Grabsch HI; Alderson D; Crosby T; Griffin SM; Mansoor W; Coxon FY; Falk SJ; Darby S; Sumpter KA; Blazeby JM; Langley RE
Lancet Oncol; 2017 Mar; 18(3):357-370. PubMed ID: 28163000
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
13. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT.
Davidson B; Gurusamy K; Corrigan N; Croft J; Ruddock S; Pullan A; Brown J; Twiddy M; Birtwistle J; Morris S; Woodward N; Bandula S; Hochhauser D; Prasad R; Olde Damink S; Coolson M; Laarhoven KV; de Wilt JH
Health Technol Assess; 2020 Apr; 24(21):1-38. PubMed ID: 32370822
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
15. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
16. INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
Lam LL; Pavlakis N; Shitara K; Sjoquist KM; Martin AJ; Yip S; Kang YK; Bang YJ; Chen LT; Moehler M; Bekaii-Saab T; Alcindor T; O'Callaghan CJ; Tebbutt NC; Hague W; Chan H; Rha SY; Lee KW; Gebski V; Jaworski A; Zalcberg J; Price T; Simes J; Goldstein D
BMC Cancer; 2023 Feb; 23(1):180. PubMed ID: 36814222
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ;
Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948
[TBL] [Abstract][Full Text] [Related]
18. AVURT: aspirin versus placebo for the treatment of venous leg ulcers - a Phase II pilot randomised controlled trial.
Tilbrook H; Clark L; Cook L; Bland M; Buckley H; Chetter I; Dumville J; Fenner C; Forsythe R; Gabe R; Harding K; Layton A; Lindsay E; McDaid C; Moffatt C; Rolfe D; Sbizzera I; Stansby G; Torgerson D; Vowden P; Williams L; Hinchliffe R
Health Technol Assess; 2018 Oct; 22(55):1-138. PubMed ID: 30325305
[TBL] [Abstract][Full Text] [Related]
19. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults.
Mai NTH; Dobbs N; Phu NH; Colas RA; Thao LTP; Thuong NTT; Nghia HDT; Hanh NHH; Hang NT; Heemskerk AD; Day JN; Ly L; Thu DDA; Merson L; Kestelyn E; Wolbers M; Geskus R; Summers D; Chau NVV; Dalli J; Thwaites GE
Elife; 2018 Feb; 7():. PubMed ID: 29482717
[TBL] [Abstract][Full Text] [Related]
20. Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.
Wojcieszek AM; Shepherd E; Middleton P; Lassi ZS; Wilson T; Murphy MM; Heazell AE; Ellwood DA; Silver RM; Flenady V
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012203. PubMed ID: 30556599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
